You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Aldeyra

Showing 1 - 25 of 30
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Atopic Dermatitis Trial in Bexley (Part 1 ADX-629 (Open-label))

Not yet recruiting
  • Atopic Dermatitis
  • Part 1 ADX-629 (Open-label)
  • Bexley, Ohio
    Bexley Dermatology Research
Feb 6, 2023

Atopic Asthma Trial in Mississauga (ADX-629, Placebo)

Completed
  • Atopic Asthma
  • Mississauga, Ontario, Canada
    Cliantha Research
Jan 9, 2023

Ethanol Intoxication Trial in Cincinnati (ADX-629, Placebo)

Recruiting
  • Ethanol Intoxication
  • Cincinnati, Ohio
    Medpace Clinical Pharmacology
Aug 2, 2022

Nephrotic Syndrome Trial in United States (ADX-629)

Not yet recruiting
  • Nephrotic Syndrome
  • Northridge, California
  • +10 more
Jan 24, 2023

Retinitis Pigmentosa Trial in Durham (ADX-2191)

Recruiting
  • Retinitis Pigmentosa
  • Durham, North Carolina
    Duke Eye Center
Sep 26, 2022

Dry Eye Disease Trial in Andover (Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator)

Completed
  • Dry Eye Disease
  • Reproxalap Ophthalmic Solution (0.25%)
  • Placebo Comparator
  • Andover, Massachusetts
    Andover Eye Associates
Jan 24, 2023

Dry Eye Syndromes Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution)

Recruiting
  • Dry Eye Syndromes
  • Reproxalap Ophthalmic Solution (0.25%)
  • Vehicle Ophthalmic Solution
  • Mississauga, Ontario, Canada
    Cliantha Research
Jun 22, 2022

Dry Eye Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution))

Completed
  • Dry Eye
  • Reproxalap Ophthalmic Solution (0.25%)
  • Xiidra® (5% lifitegrast ophthalmic solution)
  • Mississauga, Ontario, Canada
    Cliantha Research
Sep 26, 2022

Covid19 Trial in Miami (ADX-629, Placebo)

Completed
  • Covid19
  • Miami, Florida
    Medical Research Center of Miami II, Inc.
Sep 26, 2022

Sjögren-Larsson Syndrome Trial in Omaha, Hershey, Fairfax (Active topical NS2 1% dermatologic cream, Vehicle 0.0% NS2

Completed
Has Results
  • Sjögren-Larsson Syndrome
  • Active topical NS2 1% dermatologic cream
  • Vehicle placebo 0.0% NS2 dermatologic cream
  • Omaha, Nebraska
  • +2 more
Nov 16, 2022

Chronic Cough Trial in United States (ADX-629, Placebo)

Recruiting
  • Chronic Cough
  • San Diego, California
  • +13 more
Sep 21, 2022

Conjunctivitis, Allergic Trial in United States (ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of

Completed
Has Results
  • Conjunctivitis, Allergic
  • ADX-102 Ophthalmic Drops (0.5%)
  • +2 more
  • Morrow, Georgia
  • +4 more
Dec 14, 2022

Dry Eye Trial in Raynham (Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution)

Completed
  • Dry Eye
  • Reproxalap Ophthalmic Solution (0.25%)
  • Vehicle Ophthalmic Solution
  • Raynham, Massachusetts
    Andover Eye Associates (Raynham)
Aug 2, 2022

Plaque Psoriasis Trial in San Diego (ADX-629)

Completed
  • Plaque Psoriasis
  • San Diego, California
    TCR Medical Corporation
May 5, 2022

Allergic Conjunctivitis Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution)

Recruiting
  • Allergic Conjunctivitis
  • Reproxalap Ophthalmic Solution (0.25%)
  • Vehicle Ophthalmic Solution
  • Mississauga, Ontario, Canada
    Cliantha Research
May 5, 2022

Dry Eye, Dry Eye Syndromes Trial in Memphis (Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution)

Completed
  • Dry Eye
  • Dry Eye Syndromes
  • Reproxalap Ophthalmic Solution (0.25%)
  • Vehicle Opthalmic Solution
  • Memphis, Tennessee
    University Clinical Health
Mar 28, 2022

Proliferative Vitreoretinopathy Trial in United States (ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care

Recruiting
  • Proliferative Vitreoretinopathy
  • ADX-2191 (intravitreal methotrexate 0.8%)
  • Standard surgical care procedure
  • Phoenix, Arizona
  • +22 more
Jan 31, 2022

Allergic Conjunctivitis Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution)

Completed
  • Allergic Conjunctivitis
  • Reproxalap Ophthalmic Solution (0.25%)
  • Vehicle Ophthalmic Solution
  • Mississauga, Ontario, Canada
    Cliantha Research
Jan 3, 2022

Dry Eye Trial in Andover (Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution)

Completed
  • Dry Eye
  • Reproxalap Ophthalmic Solution (0.25%)
  • Vehicle Ophthalmic Solution
  • Andover, Massachusetts
    Andover Eye Associates
Dec 8, 2021

Allergic Conjunctivitis Trial in Houston (Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle

Completed
  • Allergic Conjunctivitis
  • Reproxalap Ophthalmic Solution (0.25%)
  • +2 more
  • Houston, Texas
    Slade & Baker Vision
Dec 2, 2020

Dry Eye Trial in Andover (Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution

Completed
  • Dry Eye
  • Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
  • Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
  • Andover, Massachusetts
    Andover Eye Associates
Dec 2, 2020

Dry Eye Trial in Newport Beach (Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap

Completed
  • Dry Eye
  • Reproxalap Ophthalmic Solution (0.25%) QID
  • +3 more
  • Newport Beach, California
    Eye Research Foundation
Dec 2, 2020

Sjogren-Larsson Syndrome Trial in New Haven, Omaha (ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical

Completed
  • Sjogren-Larsson Syndrome
  • ADX-102 1% Topical Dermal Cream (reproxalap)
  • Vehicle of ADX-102 Topical Dermal Cream
  • New Haven, Connecticut
  • +1 more
Nov 5, 2020

Conjunctivitis, Allergic Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%),

Completed
  • Conjunctivitis, Allergic
  • Reproxalap Ophthalmic Solution (0.25%)
  • +2 more
  • Mississauga, Ontario, Canada
    Inflamax Research Limited
May 11, 2020

Non-infectious Anterior Uveitis Trial in United States (ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic

Completed
  • Non-infectious Anterior Uveitis
  • ADX-102 Ophthalmic Solution (0.5%)
  • Vehicle of ADX-102 Ophthalmic Solution
  • Birmingham, Alabama
  • +26 more
May 15, 2020